Evidence map›Paper›PMID 37575951›Full record

ArticleTransplantation direct2023

Decreased Lymphocytic Bronchitis Severity in the Era of Azithromycin Prophylaxis.

Jesse Santos, Steven R Hays, Jeffrey A Golden, Daniel R Calabrese, Nicholas Kolaitis, Mary Ellen Kleinhenz, Rupal Shah, Aida Venado Estrada, Lorriana E Leard, Jasleen Kukreja and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation direct, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jesse SantosSan Francisco Department of Medicine, University of California, San Francisco, CA.
Steven R HaysSan Francisco Department of Medicine, University of California, San Francisco, CA.
Jeffrey A GoldenSan Francisco Department of Medicine, University of California, San Francisco, CA.
Daniel R CalabreseMedical Service, San Francisco VA Health Care System, San Francisco, CA.
Nicholas KolaitisSan Francisco Department of Medicine, University of California, San Francisco, CA.
Mary Ellen KleinhenzSan Francisco Department of Medicine, University of California, San Francisco, CA.
Rupal ShahSan Francisco Department of Medicine, University of California, San Francisco, CA.
Aida Venado EstradaSan Francisco Department of Medicine, University of California, San Francisco, CA.
Lorriana E LeardSan Francisco Department of Medicine, University of California, San Francisco, CA.
Jasleen KukrejaSan Francisco Department of Medicine, University of California, San Francisco, CA.
Jonathan P SingerSan Francisco Department of Medicine, University of California, San Francisco, CA.
John R GreenlandDivision of Pulmonary and Critical Care, Department of Medicine, School of Medicine, University of California, San Francisco, CA.
University of California, San Francisco · USSan Francisco VA Health Care System · US

Funding

Filling a Void of Research (FAVOR) Training for Transplant SurgeonsT32AI125222 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER G STOCK, Minnie M Sarwal · 2016 to 2026
$3.4M
BLRD VA IK2 BX005301NIAID NIH HHS T32 AI125222
6 · The paper itself

Abstract

Large-airway lymphocytic inflammation (LB), assessed on endobronchial biopsies, has been associated with acute cellular rejection and chronic lung allograft dysfunction (CLAD). Azithromycin (AZI) prophylaxis has been used to prevent airway inflammation and subsequent CLAD, with inconsistent results. We hypothesized that AZI prophylaxis would be associated with reduced LB, changes in bronchoalveolar lavage (BAL) immune cell populations, and improved CLAD-free survival. Methods: We compared frequencies of LB from endobronchial biopsies before (N = 1856) and after (N = 975) protocolized initiation of AZI prophylaxis at our center. LB was classified as none, minimal, mild, or moderate by histopathologic analysis. LB grades were compared using ordinal mixed-model regression. Corresponding automated BAL leukocyte frequencies were compared using mixed-effects modeling. The effect of AZI prophylaxis on CLAD-free survival was assessed by a Cox proportional hazards model adjusted for age, sex, ethnicity, transplant indication, and cytomegalovirus serostatus. Results: Biopsies in the pre-AZI era had 2-fold increased odds (95% confidence interval, 1.5-2.7; Conclusions: Decreased airway inflammation in the era of AZI prophylaxis may represent a direct effect of AZI therapy or reflect other practices or environmental changes. In this cohort, AZI prophylaxis was not associated with improved CLAD-free survival.

Identifiers

PMID37575951
PMCPMC10414707
OpenAlexW4385722959

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.